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Abstract The nitration of protein tyrosine residues by peroxy-
nitrous acid has been associated with pathological conditions.
Here it is shown, using a sensitive competitive enzyme-linked
immunosorbent assay and immunoblotting for nitrotyrosine, that
spontaneous nitration of specific proteins occurs during a
physiological process, the activation of platelets by collagen.
One of the main proteins nitrated is vasodilator-stimulated
phosphoprotein. Endogenous synthesis of nitric oxide and
activity of cyclo-oxygenase were required for the nitration of
tyrosine. The nitration was mimicked by addition of peroxyni-
trite to unstimulated platelets, although the level of nitrotyrosine
formation was greater and its distribution among the proteins
was less specific.
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1. Introduction
Platelet aggregation, induced by speci¢c agonists, leads to
both biochemical and morphological changes in the cell.
Platelets release nitric oxide (NO) during platelet aggregation,
but not at rest [1,2]. NO, which activates soluble guanylyl
cyclase leading to the formation of cGMP, inhibits platelet
activation through the action of cGMP-dependent kinases
[3] and their phosphorylation of vasodilator-stimulated phos-
phoproteins (VASPs) [4]. The platelet-derived NO limits the
activation of neighbouring platelets [5] to avoid excessive re-
cruitment of these cells into thrombi. Di¡erences in the po-
tency of platelet agonists to elicit NO biosynthesis have been
reported: collagen and arachidonic acid are the most potent,
while thrombin has a much smaller e¡ect [1,6]. During acti-
vation, platelets also form superoxide anions (O32 ) and hy-
drogen peroxide [7,8] : the peroxide strongly enhances the abil-
ity of NO to inhibit platelet aggregation [9].
NO reacts with O32 to form peroxynitrite (ONOO
3), a
potent oxidant [10], which has been shown to be released by
endothelial cells [11]. Peroxynitrite inhibits platelet aggrega-
tion, but less e¡ectively than NO [9,12^14]. The mechanism
of this inhibition has been proposed to be both dependent
[12,14] and independent [13] of cGMP. Peroxynitrite is ex-
tremely reactive and oxidises, hydroxylates and nitrates phe-
nol groups on amino acids [15] and this may account for the
presence of nitrated proteins in normal plasma [16]. Further-
more, nitrotyrosine has been found in in£ammatory condi-
tions, e.g. atherosclerotic plaques [17] and synovial £uid in
rheumatoid arthritis [18], and has been used extensively as a
marker of peroxynitrite formation in vivo.
Since both the reactants required for peroxynitrite forma-
tion, NO and O32 , are produced during the platelet activa-
tion/aggregation process, we examined the possibility of the
nitration of protein tyrosine residues. The spontaneous nitra-
tion of proteins was shown to arise as part of a normal cel-
lular process, in this case platelet activation, and that this
nitration may target speci¢c proteins in these cells.
2. Materials and methods
Prostacyclin (synthetic sodium salt), thrombin (human), bovine se-
rum albumin (BSA), NG-nitro-L-arginine methyl ester (L-NAME),
acetylsalicylic acid (ASA) and (3-[3-cholamidopropyl) dimethylammo-
nio]-1-propane-sulphonate (CHAPS) bu¡er were purchased from Sig-
ma (Poole, UK), collagen Type I (equine) from Hormonchemie (Mu-
nich, Germany) and oxadiazoloquinoxaline-1-one (ODQ) from
Tocris-Cookson Chemicals (Southampton, UK).
Biotinylated goat anti-rabbit IgG antibodies and ECL reagents
were obtained from Amersham-Pharmacia (Hertfordshire, UK), avi-
din^biotin horseradish peroxidase from Dako (Beacons¢eld, UK),
anti-nitrotyrosine was from TCS Biologicals plc (High Wycombe,
Buckinghamshire, UK) and anti-VASP antibodies from Alexis (Not-
tingham, UK). Pre-cast 10% were prepared in the laboratory and
nitrocellulose (pore size 0.45 Wm) were purchased from Novex (San
Diego, CA, USA).
2.1. Platelet preparations
Venous blood was taken with informed consent from healthy vol-
unteers, who denied taking any medication in the previous 14 days,
placed in acid-citrate-dextrose anticoagulant and centrifuged for
20 min at 150Ug to yield platelet-rich plasma (PRP). Washed plate-
lets (WP) were prepared from PRP in the presence of prostacyclin as
described elsewhere [9,19], suspended in bu¡er (NaCl 137 mM,
NaH2PO4 4.2 mM, NaHCO3 11.9 mM, KCl 2.7 mM, pH 7.4) and
diluted to a count of 3U108 platelets/ml. The platelets were allowed to
rest for 1 h at room temperature and used within the following 2 h.
To prepare cytosolic and membrane fractions, WP were sonicated
at 4‡C (Soniprep, M.S.E., UK) for 2U15 s bursts separated by a 15 s
pause and the cytosol separated from the membrane fractions by
centrifugation at 1500Ug for 10 min. The pellet, which contained
the membrane fraction, was solubilised in 0.1% CHAPS bu¡er [20].
2.2. Preparation of peroxynitrite
Sodium peroxynitrite was prepared as described previously [9]: con-
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trols were prepared by the same procedure, except that the solutions
were passed directly into water instead of NaOH, leading to immedi-
ate decomposition of the oxidant. NaOH was then added to restore
the pH to 10. The concentration of stock peroxynitrite solutions was
determined spectrophotometrically (O302 nm = 1760 M31 cm31) using
decomposed peroxynitrite as the blank.
2.3. Measurement of nitrated proteins
The nitrotyrosine content of proteins in the platelet samples was
estimated using a competitive enzyme-linked immunosorbent assay
(ELISA) developed in this laboratory [16] using nitrated (NT)-BSA
as a standard. The results were extrapolated from a semi-log plot of
the standard curve and were expressed as nmol BSA equivalents/mg
protein. The protein concentrations were analysed using a modi¢ed
Lowry method [21].
2.4. Sodium dodecyl sulfate^polyacrylamide gel electrophoresis
(SDS^PAGE) and immunoblotting
After various treatments, the reactions were stopped by addition of
an equal volume of Laemmli’s bu¡er [22]. Proteins were separated by
SDS^PAGE on 10% gels. The separated proteins were transferred to
nitrocellulose membranes using wet transfer techniques. Membranes
were blocked with BSA (0.5%) dissolved in phosphate-bu¡ered saline
(PBS)/Tween (1% PVP-10, 1% PEG, 0.2% Tween and 10 mM NaF)
for 60 min. Membranes were probed with either, anti-nitrotyrosine
(1:800) or anti-VASP (1:2000) for 60 min. The membranes were
washed several times with PBS/Tween, followed by incubation with
horseradish peroxidase-linked goat anti-rabbit IgG for 60 min. The
protein bands were visualised using ECL reagents.
In some experiments, membranes were stripped by washing with a
stripping bu¡er (100 mM mercaptoethanol, 2% SDS and 62.5 mM
Tris^HCl; pH 6.7) at 50‡C for 30 min. The membranes were washed
and probed with anti-VASP antibodies. After washing, the mem-
branes were incubated with horseradish peroxidase-linked goat anti-
rabbit IgG.
2.5. Statistical analysis
All data are presented as the mean þ S.E.M. of at least three inde-
pendent experiments, unless otherwise stated. Statistical analysis was
performed using Student’s unpaired t-test.
3. Results
3.1. Nitration of proteins following agonist-induced activation
of platelets
Low levels of nitrated proteins were found in most, but not
all unstimulated platelets (Fig. 1) as measured by ELISA. In
the cytosolic fraction 0.18 þ 0.08 nmol nitrotyrosine/mg pro-
tein were found, but the basal level of nitration in the mem-
brane fraction was higher at 0.31 þ 0.08 nmol/mg protein. The
CHAPS bu¡er used to solubilise the membrane fraction was
found to have no e¡ect on the reproducibility of the ELISA.
The activation of WP by collagen (0.2^20 Wg/ml) for 1 min
led to a concentration-dependent increase in the formation of
nitrotyrosine residues on platelet proteins in the absence of
exogenous peroxynitrite. The greatest e¡ect was found with
collagen (20 Wg/ml) where nitrotyrosine was increased to
0.75 þ 0.15 nmol nitrotyrosine/mg protein, an almost four-
fold increase above basal levels (P6 0.01) (Fig. 1). Collagen
(2 Wg/ml) increased nitrotyrosine levels on cytosolic proteins
from a basal level of 0.18 þ 0.08 nmol to 0.56 þ 0.1 nmol nitro-
tyrosine/mg protein (P6 0.05) after 1 min. However, at lower
concentrations of collagen (0.2 Wg/ml) the elevation in nitro-
tyrosine did not reach statistical signi¢cance. There was some
variation between platelet preparations, from a two- to a ¢ve-
fold increase in nitrotyrosine, which may re£ect the varying
responsiveness to collagen of platelets taken from di¡erent
donors. No increase in the levels of nitrated proteins was
detected in the membrane fractions at any concentration of
collagen. In experiments where thrombin (0.02^0.2 U/ml) was
used to stimulate platelets, it was less e¡ective in causing
platelet nitration and the apparent increase was not statisti-
cally signi¢cant (not shown). The presence of EGTA (1 mM)
abolished the collagen-induced formation of nitrotyrosine (not
shown).
The experiments were repeated in the presence of L-NAME,
a competitive inhibitor of nitric oxide synthase (NOS), used at
submaximal concentrations (100 WM). Collagen (20 Wg/ml)
induced 0.75 þ 0.15 nmol nitrotyrosine/mg protein, while in
the presence of L-NAME this was reduced to 0.42 þ 0.09
nmol (P6 0.05) (Fig. 1). The reduction in nitrotyrosine sug-
gests that endogenously synthesised NO was required for the
formation of a nitrating species and subsequently nitrotyro-
sine.
The presence of nitrotyrosine in speci¢c platelet proteins
was determined by immunoblotting with an anti-nitrotyrosine
antibody. Low levels of nitrotyrosine were detected in the
proteins of resting platelets (Fig. 2A, lane 2) particularly those
with molecular weights of 46 to 50 kDa. However, stimulation
of the platelets with collagen led to a marked increase in the
extent of nitration in these proteins. The greatest e¡ect was
again observed with 20 Wg/ml collagen (Fig. 2A, lane 5), con-
¢rming results described above with the ELISA on total plate-
let proteins. The presence of L-NAME (100 WM) also reduced
the signal for nitrotyrosine in the bands of nitrated proteins.
Furthermore, the pre-incubation of platelets with ASA (1 mM)
returned the extent of protein nitration of VASP to those of
resting platelets or lower. ODQ (10 WM), a speci¢c inhibitor
of soluble guanylyl cyclase [23], had no e¡ect on the amounts
of nitrotyrosine detected.
The proteins which were most strongly nitrated following
activation of platelets by collagen, molecular weights of 46
Fig. 1. Protein bound nitrotyrosine formation in collagen-stimulated
platelets. WP were incubated with collagen (0.2^20 Wg/ml) for 1 min
with stirring at 37‡C. The membrane and cytosolic fractions were
prepared as described in Section 2. Nitrotyrosine was measured by
a competitive ELISA. The data shows the nitrotyrosine formed in
the cytosol after treatment of collagen (no ¢ll) and membrane
(hatched ¢ll). In some experiments platelets were preincubated with
L-NAME for 30 min prior to the addition of collagen (black ¢ll).
The results are expressed as nmol nitrotyrosine/mg protein and rep-
resent the mean þ S.E.M. of four independent experiments:
*P6 0.05 or **P6 0.05 for nitration compared to basal levels,
#P6 0.05 for the e¡ects of L-NAME.
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and 50 kDa, were shown to be VASP, representing the phos-
pho (50 kDa) and de-phospho (46 kDa) forms of the protein,
by stripping and re-probing the membrane with anti-VASP
antibody (Fig. 2B). This was con¢rmed by immuno-precipita-
tion of VASP with this antibody, re-running on a gel and
probing with anti-nitrotyrosine antibody to reveal nitrated
protein only at the 46 and 50 kDa bands (not shown).
3.2. Nitration of platelet proteins by exogenous peroxynitrite
The extent of nitration of proteins induced by collagen was
compared to that in platelets exposed to solutions of authentic
peroxynitrite. This led to a concentration-dependent increase
in the formation of nitrotyrosine residues on both membrane
and cytosolic proteins (Fig. 3). Nitrotyrosine levels were great-
er than those previously induced by agonist-stimulated plate-
let activation. However, as with spontaneous nitration, nitro-
tyrosine was found to be higher in the proteins from the
cytosolic fraction. Peroxynitrite (3 WM) induced 12.6 þ 3.2
nmol nitrotyrosine/mg protein in the cytosolic fraction and
1.6 þ 0.3 nmol/mg protein in the membrane fraction (Fig. 3).
The presence of exogenous glutathione (1 mM) protected
platelet proteins, causing an almost complete abolition of ni-
tration (not shown). Decomposed peroxynitrite did not raise
nitrotyrosine concentrations signi¢cantly above the levels
found basally (Fig. 3).
Immunoblotting of the peroxynitrite-treated samples
showed that the oxidant caused the nitration of a broad spec-
trum of di¡erent proteins of which VASP was only a minor
contributor (not shown). This is in contrast to collagen, which
induced a more selective process of nitration.
4. Discussion
In the present study we investigated whether the nitration
of proteins could be formed as part of a normal physiological
process. Low levels of nitration were detected in the majority
of, but not all, samples of resting platelets and has been ob-
served previously in unstimulated cell lysates of cultured en-
dothelial cells [24] and in human plasma [16]. The basal levels
of nitration found in platelets suggested that they were ex-
posed to a nitrating species either in vivo, or possibly by
activation of the cells during the isolation process.
The activation of platelets with collagen, but not thrombin,
led to an increase in the levels of cytosolic nitration. This is
direct evidence that nitration may occur as part of a normal
physiological process. The reduction in nitrotyrosine forma-
tion in the presence of L-NAME indicates that endogenously
synthesised NO is a key requirement for the formation of
nitrating species and subsequently nitrotyrosine. The lower
rates of synthesis of NO in thrombin-stimulated platelets
[1,6] probably accounts for the inability of thrombin to induce
signi¢cant nitration. ASA was also found to be an inhibitor of
the nitration process. Activation of prostaglandin H synthase-
2 leads to the formation of a tyrosyl radical within the enzyme
complex that may react with NO to form nitrotyrosine leading
to autonitration of this enzyme and possibly other proteins
[25]. Alternatively, the formation of thromboxane A2 during
platelet activation will be inhibited by ASA. This eicosanoid
acts primarily to increase platelet [Ca2]i leading to the acti-
vation of platelet NOS. Thus, in the presence of ASA no
nitrating species would be formed.
The nitration of platelet proteins following activation by
collagen is not uniform across all platelet proteins. Firstly,
nitration occurred mainly among the cytosolic proteins. Fur-
Fig. 2. A: Protein-bound nitrotyrosine formation in collagen-stimu-
lated platelets. WP were incubated with collagen (0.2^20 Wg/ml) for
1 min with stirring at 37‡C. In the same experiment the platelets
were incubated with L-NAME (100 WM), ASA (1 mM) or ODQ (10
WM) for 30 min, prior to addition of collagen. Platelets were lysed
with Laemmli’s bu¡er and subjected to SDS^PAGE and immuno-
blotting as described in Section 2. Lane 1, NT-BSA; lane 2, resting
platelets; lane 3, collagen 0.2 Wg/ml; lane 4, collagen 2 Wg/ml; lane
5, collagen 20 Wg/ml; lane 6, collagen 20 Wg/ml+ODQ 10 WM; lane
7, collagen 20 Wg/ml+L-NAME (100 WM); lane 8, collagen 20 Wg/ml
after pre-incubation with 1 mM ASA for 30 min. The blot is repre-
sentative of four independent experiments. B: Identi¢cation of
VASP as a possible target for endogenous nitration. Experimental
protocol was identical to that of (A), except the membranes were
stripped and re-probed with anti-VASP antibody. Lane 1, resting
platelets; lane 2, +collagen 0.2 Wg/ml; lane 3, collagen 2 Wg/ml; lane
4, collagen 20 Wg/ml; lane 5, collagen 20 Wg/ml+ODQ (10 WM);
lane 6, collagen 20 Wg/ml+L-NAME (100 WM); lane 7, collagen 20
Wg/ml after pre-incubation with ASA 1 mM. The blot is representa-
tive of four independent experiments.
Fig. 3. Peroxynitrite-induced nitration of platelet proteins. Peroxyni-
trite was added to WP and incubated for 1 min at 37‡C with con-
tinuous stirring. The platelets were separated into cytosolic and
membrane fractions as described in the Section 2. Nitrotyrosine was
then measured using a semi-quantitative ELISA. Results are ex-
pressed as nmol nitrotyrosine/mg protein and represent the mean þ
S.E.M. of ¢ve independent experiments. **P6 0.01 for nitration
compared to basal levels.
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thermore, speci¢c proteins appear to be targeted for nitration
during the activation process. One of these proteins was iden-
ti¢ed as VASP, a protein involved in cytoskeletal rearrange-
ment during platelet aggregation [26]. VASP is a primary
target for both cGMP- and cAMP-dependent kinases leading
to the phosphorylation of two serine and one threonine resi-
dues [27]. The phosphorylation of serine 157 leads to a change
in the apparent molecular weight from 46 to 50 kDa, but both
forms appear to be capable of being nitrated. VASP has four
tyrosine residues and their functional signi¢cance is unknown.
The consequences of the nitration of VASP on its function
require further investigation. The identity of the other protein
bands that appear to be nitrated has not been established.
The exposure of platelets to low concentrations of authentic
peroxynitrite, capable of the inhibition of platelet activation
[10], caused extensive nitration of platelet proteins again
mainly in the cytosolic fraction (Fig. 3), a phenomenon al-
ready observed both in platelets [28] and neuroblastoma cells
[29]. This suggests that peroxynitrite formed extracellularly,
e.g. by the endothelium, may di¡use into platelets (or other
cells) and modify their cytosolic proteins [30]. The nitration
occurred over a broad spectrum of proteins, appearing to be
indiscriminate, but much more intense than after stimulation
with collagen. This indicates that when platelets are exposed
to collagen, the formation of endogenous NO and peroxyni-
trite is not su⁄cient to inhibit their activation. It is possible
that the nitration process may be part of a mechanism by
which nitric oxide limits the extent of the activation process
in platelets by inhibiting the activation of neighbouring plate-
lets. Furthermore, the chronic exposure of platelets to both
NO and peroxynitrite, at low levels from endothelial cells,
may lead to a more selective action on speci¢c proteins such
as VASP. This may prevent the formation of thrombi unless a
major stimulus such as the exposure of collagen or the release
of thrombin occurs.
It is still an open question whether collagen-induced nitra-
tion is a process of physiological signi¢cance. The pre-treat-
ment of cells with peroxynitrite can substantially reduce the
level of tyrosine phosphorylation [24,28] thereby compromis-
ing cell signalling. Conversely, a recent study has shown that
c-Jun NH2-terminal kinase is regulated by tyrosine nitration
[31]. This may suggest that endogenous nitration may serve
some regulatory function.
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